RNA therapy company Sirnaomics has raised $47m to develop its technology and work on its STP705 product aimed at tackling non-melanoma skin cancer and the reduction of hypertrophic scars. The second part of the firm’s series C round was led by China Resources and Charoen Pokphand joint venture CR-CP Life Sciences Fund, backed by Legend Sky Investment, Rich Yield Capital and Rolling Boulder Investment. In a press release, CEO David Liu said that his firm is “excited about our partnership with Sirnomega in developing this new drug for melanoma.”
RNA therapy company Sirnaomics has raised $47m to develop its technology and work on its STP705 product aimed at tackling non-melanoma skin cancer and the reduction of hypertrophic scars. The second part of the firm’s series C round was led by China Resources and Charoen Pokphand joint venture CR-CP Life Sciences Fund, backed by Legend Sky Investment, Rich Yield Capital and Rolling Boulder Investment. It added $22m to the $25m raised during the first stage if the round which was led by Yuexiu New Industrial Investment backed by Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment.